A 19-year-old man was admitted in our tertiary care center in August 2014 for a 10-kg weight loss in a few months (48 kg, 1.80 m, and body mass index, 14.8 kg/m 2 ), claudication in the lower limbs after a 500-m distance and a postprandial abdominal pain associated with mild renal insufficiency and proteinuria with no hypertension (100/80 mm Hg). The patient had no medical history and was an active smoker (tobacco and cannabis, estimated consumption: 2 pack-years). Laboratory parameters were elevated leukocyte count (13×10 9 /L), C-reactive protein level (55 mg/L), creatinine (14 mg/L), and B-natriuretic peptide (4246 pg/mL). No thrombophilia, autoimmune disorders, or viral infections were identified. The patient underwent a B-mode Doppler ultrasound that showed multiple proximal arterial occlusions and stenoses of large vessels confirmed by a computed tomographic angiography: occlusions of bilateral subclavian arteries, superior and inferior mesenteric arteries, and right renal artery with kidney atrophy were found ( Figure 1A) . Furthermore, significant stenoses of celiac artery, left renal artery ( Figure 1B ), right internal iliac artery, and bilateral superficial femoral arteries were identified. A discrete circumferential thickening of the abdominal aorta was suggestive of aortitis. Cervical magnetic resonance angiography showed a complete occlusion of both subclavian and vertebral arteries (Figure 2 ). Transthoracic echocardiography revealed a severe left ventricular (LV) systolic dysfunction (LV ejection fraction was 27%), with elevated LV filling pressure (E/e′=16) and no right ventricular dysfunction (Movies I and II in the Data Supplement). Takayasu arteritis was diagnosed according to Ishikawa-Sharma and the American College of Rheumatology criteria. An anticoagulant treatment using low-molecular-weight heparin was initiated together with intravenous steroids, aspirin, and β-blockers. Few days later, a positron emission tomographic (PET) scan revealed an hypermetabolism located in the ascending thoracic aorta and the proximal portion of the aortic arch and the right external iliac artery ( Figure 3A and 3B). A cardiovascular magnetic resonance imaging showed a left ventricular dilation with hypokinesia and severe LV ejection fraction impairment of 18% associated with a concentric remodeling (mass/end-diastolic volume close to 1; Figure 4A ; Movie III in the Data Supplement), without any argument for an acute myocarditis or myocardial infarction. Given the severity of arterial lesions and clinical symptoms, a short-term surgical treatment was planned after the initiation of intravenous tocilizumab (8 mg/kg). A dramatic improvement of cardiac function (LV ejection fraction, 35%; laboratory parameters on Figure 5 ) occurred in 10 days. However, the patient presented an acute mesenteric ischemia requiring an urgent aortomesenteric and aortohepatic bypass using the great saphenous vein and a prosthetic enlargement patch on the left renal artery. Histological examination of the excised aorta showed a thickening of the aortic wall with an intima fibrosis and incipient on the media, a mild lymphocytic inflammation without granuloma or giant cell, and no damage of the vasa vasorum ( Figure 6A and 6B) . Monthly tocilizumab pulses were continued until 18 months of follow-up, and glucocorticoids tapering began 1 month after surgery. No active vasculitis was identified by PET scan after 3 months of treatment ( Figure 3C and 3D) . The patient recovered a nearly normal heart function ( Figure 4B ; Movies IV through VI in the Data Supplement). Eighteen months later, Takayasu disease was inactive and most clinical manifestations had disappeared.
Thus, the present case reports the efficacity and organ response to the anti-interleukin-6 receptor antibody (tocilizumab) associated with steroids as a first-line therapy in a patient with severe Takayasu disease before surgery. In this setting, most commonly used agents include corticosteroids and methotrexate, azathioprine, or mycophenolate mofetil. In patients who remain resistant or intolerant to these agents, biological drugs including tumor necrosis factor inhibitors Dramatic Response to Tocilizumab in Takayasu Disease (infliximab) and tocilizumab are promising. 1 In the presence of a life-threatening arterial stenosis or occlusion, the mainstay of treatment is urgent revascularization of affected organs using surgical bypass, which is associated with lower morbidity-mortality than endovascular intervention. 2 Of note, as a general rule, both endovascular intervention and surgical procedures should be avoided during the active phase of the disease to decrease the risk of vascular complications (eg, restenosis). 2 In our case, the patient was categorized in grade V of disease severity. 3 Therefore, a quick improvement was needed before revascularization to minimize postoperative complications. Indeed, tocilizumab was effective on both clinical laboratory and imaging parameters. Furthermore, reviews confirmed that tocilizumab may be an effective steroid-sparing option for rapid control of refractory disease activity in patients with Takayasu arteritis. 1, 4 Finally, it has been shown that tocilizumab is efficient and well tolerated in patients with refractory Takayasu arteritis 1 ; based on our observation, it may be now an alternative for first-line therapy in selected cases.
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